In the ever-evolving battlefield of chronic inflammation and autoimmune disorders, one class of drugs is quietly leading the charge — Tumor Necrosis Factor Alpha (TNF-α) Inhibitors. Once reserved for niche autoimmune therapies, these biologics are now gaining widespread traction across multiple disease areas. The global Tumor Necrosis Factor Alpha Inhibitors Market is...